Iovance Biotherapeutics, Inc. (IOVA) shares were trading at $2.3500 as of January 13th. The company is pursuing a high-risk Believer Strategy, funding operations through equity dilution rather than accepting a low valuation. Management and insiders believe in the long-term potential of the Tumor Infiltrating Lymphocyte platform, especially in lung cancer.

The valuation gap between market perception and internal expectations has frozen acquisition activity. Iovance’s low gross margins make it cash intensive, but the company’s rare asset in Amtagvi is defensible. A large acquirer could potentially lift margins and transform the company, but there are risks if margins do not improve.

Bio-Techne Corporation (TECH) has seen a 38.45% stock price increase due to improving organic growth and stability in instruments. A bullish thesis on Iovance Biotherapeutics (IOVA) emphasizes its high risk, high reward profile, acquisition potential, and internal conviction as core drivers for the company.

Read more at Yahoo Finance: Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory